Form 4: Arcus Biosciences General Counsel Sells Shares to Cover Tax Obligations

Arcus Biosciences' General Counsel, Carolyn C. Tang, sold 11,339 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Summary

• Carolyn C. Tang, General Counsel of Arcus Biosciences, sold 11,339 shares of common stock on December 15, 2024.
• The sale was executed at a price of $16.08 per share.
• This transaction was a 'net settlement' by the company to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).
• Following the transaction, Ms. Tang directly owns 100,623 shares of Arcus Biosciences common stock.

Sentiment

Score: 5

Explanation: This is a neutral event, as it is a routine transaction for tax purposes and does not indicate a change in the executive's outlook on the company.

Industry Context

This is a routine transaction for company insiders to manage their tax obligations related to equity compensation. It is common for executives to sell shares to cover taxes when RSUs vest.

Comparison to Industry Standards

• Similar transactions are common across the biotechnology industry, where equity compensation is a significant part of executive pay.
• Many companies use net settlement of RSUs to cover tax obligations, which is a standard practice.
• Comparable companies such as Gilead Sciences and Regeneron Pharmaceuticals also see similar Form 4 filings from their executives.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale for tax purposes.

Key Dates

Keywords

Arcus Biosciences, insider trading, Form 4, stock sale, restricted stock units, tax obligations, Carolyn C. Tang, General Counsel